Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Mendus

    MCap

    SEK327m

    Last close

    SEK6.42

    ▲ −0.07 (−1.08%)

    Metals One

    MCap

    GBP4m

    Last close

    GBP0.01

    ▲ 0.18 (19.44%)

    Cleantech Lithium

    MCap

    GBP8m

    Last close

    GBP0.07

    ▲ 0.00 (0.00%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Newron Pharmaceuticals – executive interview

Newron Pharmaceuticals – executive interview

Newron Pharmaceuticals — 2 videos in collection

More on this equity

In this video, we speak with Stefan Weber, CEO of Newron Pharmaceuticals. We discuss the company’s registrational ENIGMA-TRS Phase III programme, the setting that evenamide is targeting and the licensing deals Newron has secured. Stefan also summarises the key milestones and catalysts that investors should watch out for across the next couple of years.

Newron Pharmaceuticals is a specialist in central nervous system drug development, and lead candidate evenamide is gearing up for two pivotal studies: ENIGMA-TRS 1 (international) and ENIGMA-TRS 2 (US focused). The candidate is backed by promising clinical data, specifically in the treatment-resistant schizophrenia sub-population. The Phase III programme is anticipated to conclude in Q426, after which, management plans to file for regulatory approval in all major geographies, including Europe and the US.

< Previous

You may also be interested in these:

Healthcare

Newron Pharmaceuticals – EKF interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free